Lupus & antiphospholipid syndrome

Maternal and fetal outcomes in pregnancy complicated by pre-existing lupus nephritis: Insights from a developing country Pakistan

LupusPublished Retrospective cohort study

Authors' conclusion

The maternal and fetal outcomes in pre-existing LN depend on the disease activity at the time of conception. No correlation was found between International Society of Nephrology/Renal Pathology Society (ISN/RPS) classes of LN and adverse disease and pregnancy outcomes.

Study context

Population
Women with biopsy-proven lupus nephritis (LN) who conceived at least 6 months after diagnosis, Sindh Institute of Urology and Transplantation (SIUT), Pakistan, July 1998–June 2018
Participants
52 women89 pregnancies
Outcome
Maternal and fetal outcomes
Follow-up
Minimum 12 months after child birth
Methodological detailssingle-centre
  • Single-centre

Main finding

As reported in the abstract

Pregnancy outcomes (of 89 pregnancies)
Successful pregnancies
56 (62.9%)
Fetal complications (spontaneous abortion, stillbirth, perinatal death, intrauterine growth retardation (IUGR))
33 (37.07%)
Vaginal deliveries
33 [58.92%]
Caesarean sections
23 [41.07%]
Renal flare
33 (37.1%)
Pre-eclampsia
15 (16.9%)

Observational data: associations, not effects.

Further findings

Maternal and fetal outcomes by LN class (proliferative LN in 56 (62.9%) cases)

No significant differences in relation to LN classes
P = 0.58

Disease outcomes by disease activity at conception · 12 months

Significantly poor in those with active disease at conception
P < 0.05

Maternal death

Maternal deaths
1

Safety

Renal outcomes · 12 months

Deterioration in renal function
10 (11.2%)
Dialysis-dependent
5 (5.6%)

Original publication

Maternal and fetal outcomes in pregnancy complicated by pre-existing lupus nephritis: Insights from a developing country Pakistan. Lupus. Published 9 April 2024. doi:10.1177/09612033241246642

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.